Oxford Biomedica plc (OTCMKTS:OXBDF – Free Report) – Equities research analysts at Cantor Fitzgerald dropped their FY2024 earnings per share (EPS) estimates for Oxford Biomedica in a research note issued on Tuesday, April 30th. Cantor Fitzgerald analyst R. Bienkowski now expects that the company will earn ($0.22) per share for the year, down from their previous estimate of ($0.19). The consensus estimate for Oxford Biomedica’s current full-year earnings is ($0.38) per share.
Oxford Biomedica Stock Performance
OXBDF opened at $3.79 on Friday. The business has a fifty day moving average of $2.57 and a 200 day moving average of $2.54. Oxford Biomedica has a 52-week low of $2.09 and a 52-week high of $6.02.
About Oxford Biomedica
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.
See Also
- Five stocks we like better than Oxford Biomedica
- What is a Special Dividend?
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.
